Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402657 | 0.83 | DGAT1 (0.42) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL720443 | 0.78 | GCK (0.46) | GCKDGAT1SOAT2SOAT1DGAT2 | |
| SCHEMBL717004 | 0.71 | GCK (0.38) | GCKDGAT1KDM4ENPC1RAB9A | |
| SCHEMBL26676605 | 0.68 | SLC26A4 (0.62) | KDM4ESMN1; SMN2 | |
| SCHEMBL722328 | 0.68 | GCK (0.36) | GCKDGAT1SOAT2SOAT1DGAT2 | |
| SCHEMBL718963 | 0.66 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL719057 | 0.64 | DGAT1 (0.42) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL26676526 | 0.64 | SLC26A4 (0.60) | KDM4ESMN1; SMN2 | |
| SCHEMBL26676574 | 0.64 | SLC26A4 (0.60) | KDM4ESMN1; SMN2 | |
| SCHEMBL24485192 | 0.64 | SLC26A4 (0.58) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCK 132/4885DGAT1 869/4885SOAT2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.